GlassScriptPhysician profile
Cara Erkut
NPI 1134440266
$13,853.82
in general payments reported to CMS, 2019-2025
18 companies · $1,351 in 2025
The $1,351 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12K · 2024: $753 · 2025: $1,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,057 · Education: $46.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,056.91 |
| Education | $46.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $11,750.00 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $525.72 | 2024-2025 | Caplyta |
| Abbvie INC. | $424.09 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $202.44 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $198.27 | 2024-2025 | Spravato |
| Neurocrine Biosciences, INC. | $151.75 | 2024-2025 | Ingrezza |
| Neuronetics, INC. | $120.45 | 2024-2025 | Neurostar Tms Therapy System |
| Lundbeck LLC | $105.96 | 2024-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $92.91 | 2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $63.70 | 2024-2025 | Austedo Xr, Austedo Xr |
| Idorsia Pharmaceuticals US INC | $37.45 | 2024-2025 | Quviviq, Quviviq |
| Janssen Scientific Affairs, LLC | $37.20 | 2025 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $34.09 | 2025 | Cobenfy |
| Alkermes, INC. | $26.13 | 2025 | Vivitrol |
| Axsome Therapeutics, INC. | $24.63 | 2025 | Auvelity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $21.51 | 2024 | Trintellix |
| Noven Therapeutics, LLC | $20.99 | 2024 | Secuado, Xelstrym |
| Collegium Pharmaceutical, INC. | $16.53 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cara Erkut listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.